Pre-clinical biotech firm Mablink Bioscience, known for pioneering next-gen antibody-drug conjugates through its PSARLink™ platform, has just announced its acquisition by Eli Lilly and Company. PSARLink™, an innovative hydrophilic linker utilizing a polysarcosine arm, holds promise for expanding the therapeutic potential of ADCs. Jean-Guillaume Lafay, CEO of Mablink, sees this acquisition as a strong endorsement of their approach and technology, aligning values and expertise with Lilly to potentially bring transformative cancer therapies to patients with high unmet medical needs. Approval from the French Ministry of the Economy is pending for this transaction.
Mablink Bioscience (“Mablink”), a pre-clinical biotechnology company pioneering the development of next-generation antibody-drug conjugates (ADCs) via its PSARLink™ proprietary platform, today announced an agreement to be acquired by Eli Lilly and Company (“Lilly”).
PSARlink™, an innovative hydrophilic linker using a polysarcosine arm, holds the potential for broadening the therapeutic index of ADCs to unleash their full therapeutic impact.
Jean-Guillaume Lafay, Mablink’s Chief Executive Officer, stated: “Mablink’s agreement to be acquired by Lilly is a strong endorsement of our approach, our technology, and our team. The values we share with Lilly, and our combined expertise are also a unique opportunity to leverage Mablink’s capabilities and endeavors to potentially bring transformative therapies to cancer patients with high unmet medical needs. Our thanks go to all inside and outside Mablink who have supported our efforts and development since inception.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The transaction is subject to approval from the French Ministry of the Economy.
Source: Biospace